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Apoptosis is a key determinant of major pathological processes, including chronic cardiac failure. We developed and tested in vitro
a novel system to induce cardiomyocyte-speci�c apoptosis by virus-mediated delivery of a conditional transgene.e entire system
was packaged in a lentiviral vector. We used the cardiomyocyte-speci�c Na+-Ca2+ exchange promoter to control the transcription
of the reverse tetracycline transactivator, while the transgene expression was driven by the tetracycline-responsive element. e
proapoptotic transgene of choice was the short isoform of the apoptosis-inducing factor, known to quickly induce the caspase-
independent apoptosis when overexpressed in cells. Transduction of cardiomyocyte cells with this vector caused a tetracycline-
regulated induction of apoptosis, which was not observed in noncardiac cells. erefore, our system proved a valuable molecular
tool for inducing controlled apoptosis in selected cells. Furthermore, the vectorwe developed is suitable for “lentivirus transgenesis,”
an interesting strategy recently proposed for the genetic manipulation of animals other than mice, including large mammals.
1. Introduction
Apoptosis is a key process involved in the pathogenesis
of major diseases aﬀecting the immune, nervous, gastroen-
teric, and cardiovascular system [1]. For instance, studies in
humans and in dogs have documented the presence of
approximately 3000 apoptotic cells per million in tissue har-
vested from failing hearts [2–4]. is number might seem
very small and pathologically insigni�cant; however, studies
in genetically modi�ed mice have shown that a few hundred
apoptotic cells per million are suﬃcient to cause dilated
cardiomyopathy [5, 6], a malignant cardiac disease that, in
humans, accounts for 50% of the heart transplants [7]. It
should also be bear in mind that apoptosis, once triggered, is
a rapid process (24–48 h) and consequently any histological
evaluation provides a limited “snapshot” of a dynamic and
rapid sequence of cell deaths.
Given the importance of apoptosis as a pathogenic mech-
anism, inducing this particular form of cell death in animal
models can provide important insights. Ideally, apoptosis
induction should be restricted to selected organs or systems
and adequately controlled to avoid fatal massive systemic
damage. While such requisites can be met in conditional
transgenic mice, genetic manipulations are more challenging
in clinically relevant large animalmodels. A potential strategy
in an adult organism is the induction of apoptosis in selected
organs by virus-mediated delivery of conditional transgenes.
Alternatively, controllable transgenes could be stably incor-
porated in cells, via viral vectors, during the embryonic life
for later activation [8]. However, no vector-carried transgene
system, to date, has been developed to induce apoptosis in a
controllable fashion. Nevertheless, a possible candidate gene
for such a strategy is the apoptosis-inducing factor (AIF).
Two complementary routes leading to programmed cell
death have been characterized, namely, the caspase-depen-
dent and caspase-independent pathways, which diﬀer in the
events needed to trigger the apoptotic cascade [9]. AIF was
the �rst identi�ed protein involved in caspase-independent
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cell death [10]. Recent studies have characterized a novel
AIF isoform called AIFshort (AIFsh), which comprises 7
exons derived from exon 10 to 16 of AIF. e resulting cyto-
solic protein corresponds to the C-terminal part of AIF, lack-
ing its N-terminal domain, and is able to trigger caspase-
independent cell death upon expression in recipient cells by
means of inducing chromatin condensation and large scale
(50 kb) DNA fragmentation [11].
Given our speci�c interest in lentivirus-mediated gene
transfer [12, 13] and its cardiovascular applications [14], here,
we developed a lentiviral vector for cardiomyocyte-speci�c,
conditional expression of AIFsh. is vector contains two
transcriptional units in tandem, one coding for the inducible
prokaryotic tetracycline (Tet) activator (rtTA), which was
placed under the control of a cardiac-speci�c promoter, and
the second the AIFsh gene regulated by the rtTA-responsive
element.
2. Materials andMethods
2.1. Cell Lines and Culture. Human renal epithelial (HEK
293T) and HeLa cell lines where cultured in DMEM (Lonza,
Basel, Switzerland) supplemented with 10% fetal bovine
serum (FBS), glutamine and antibiotics; mouse tumoral
cardiac HL-1 cell line (kind gi from Professor W. Clay-
comb, Department of Biochemistry and Molecular Biology,
LSUHSC, New Orleans, LA, USA [16]) was cultured in Clay-
comb Medium (SAFC, St. Louis, MO, US) supplemented
with 10% FBS, antibiotics, glutamine, and norepinephrine
(according to Prof. Claycomb recommendations). HL-1 car-
diac phenotype and easiness of propagation render these cells
a versatile tool as surrogate of cardiomyocytes for in vitro
studies [16].
2.2. Construction of Dual-Promoter Lentiviral Vectors. Car-
diac-speci�c, Tet-regulated lentiviral vectors were developed
using an approach similar to the one described by Gascòn
and colleagues [15] in neurons. In the Tet-on system, the
rtTA transactivator mediates the transcription of a transgene
controlled by the TRE inducible promoter. Transcriptional
activation is positively regulated by the presence of Tet, which
allows the binding of rtTA to the TRE promoter, thereby pro-
moting transgene expression.erefore, regulated expression
with theTet-on system requires the delivery in the same target
cell of both the rtTA transactivator and the transgene.
e lentiviral backbone used in this study was derived
from pTY2-CMV-GFP, an optimized self-inactivating (SIN),
integrase-defective human immunode�ciency virus type-1
(HIV-1) vector obtained by Dr. A. Cara, Istituto Superiore di
Sanità, Rome, Italy [17]. For our purposes, the parental pTY2-
CMVGFP vector was modi�ed in the multiple cloning site
(MCS), which was completely redesigned between the KpnI
and SalI restriction sites, and the CMV-GFP cassette that was
replaced by an inducible, cardiac cell speci�c expression sys-
tem. e inducible expression vector was obtained by insert-
ing the NCX-1 promoter [18], into pTY2-CMV-GFP. is
promoter drives the expression of the reverse repressor of the
rtTA gene. Another expression cassette downstream contains
the TRE sequence placed upstream the hAIFsh coding
sequence [11] (Figure 1(c)).
MCS was reshaped by means of two synthetic oligonu-
cleotides, bearing the restriction sites KpnI-AscI-NcoI-
EcoRV-BglII-XhoI-XbaI-SacII-NheI-SalI (KpnI and SalI
designed as protruding ends upon annealing). e oligo-
nucleotides were phosphorylated with T4 PNK (New
England Biolabs, Ipswich, MA, USA), annealed, and then
ligated into pTY2-CMV-GFP vector cut with KpnI and SalI
enzymes, thus generating the pTY2-CMV-GFP-MCS vector.
e CMV-GFP cassette was �nally removed by SalI/ClaI
digestion followed by Klenow protrusive end blunting and
ligation, thus obtaining pTY2-MCS.
AIFsh sequence was ampli�ed from p3xFLAG-AIFsh (a
kind gi from Dr. Susin [11]) and cloned in the new MCS
between the SacII and NheI sites; TRE element was sub-
cloned from pTRE2 (Clontech Europe, France) by means
of digestion with XhoI and SacII and subsequent liga-
tion upstream AIFsh, thus obtaining the pTY2-TRE-AIFsh.
ereaer, rtTA sequencewas ampli�ed frompTetON (Clon-
tech Europe, France) and cloned between AscI and EcoRV
sites. Finally, the NCX1 promoter sequence was ampli�ed
from pNCX1831 plasmid (a gi from Dr. Menick [18]) and
cloned into the AscI site upstream of rtTA.e correct orien-
tation and the absence ofmutations in all fragments were ver-
i�ed by sequencing. e resulting construct, named pTY2-
NCX1-rtTA-TRE-AIFsh (pNRTA), was used for lentiviral
vector production.
2.3. Lentivirus Production. Recombinant lentiviruses were
produced by a three-plasmid transfection procedure as
described elsewhere [12, 13, 19]. Brie�y, HEK 293T cells were
cotransfected with the pNRTA vector or the pTY2-CMV-
GFP vector, the packaging vector pΔ8.91, and a vector
encoding the G-protein of the vesicular stomatitis virus
(VSV-G).
e virus supernatants were collected 48 hours aer
transfection, pooled, and �ltered through 0.45𝜇𝜇m �lters.
Viral titers were calculated bymeasuringHIV capsid p24 titer
in the viral supernatants by an enzyme-linked immunosor-
bent assay (ELISA) (Innogenetics, Gent, Belgium).
2.4. Lentivirus-Mediated Transduction. Transduction of cell
lines was performed in 12-well plate, 1mL volume per well,
according to Bonci et al. [20]. Lentivirus supernatants were
added to 105 target cells (400 ng p24/well, in Opti-MEM 2%
FBS) and incubated for 6 hours. en cells were washed and
the medium changed to Claycomb medium 10% FBS. 48
hours aer transduction, cells were assayed for inducible
apoptosis upon the administration of 1 𝜇𝜇g/mL Tet (see
below).
e same protocol was used forHeLa cells with the excep-
tion of postinfectionmedium, which was switched to DMEM
10% FBS.
Eﬃciency of transduction was evaluated using the same
amount of pTY2-CMV-GFP construct and testing the per-
centage of green cells aer 48 hours by �ow cytometry.
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Ψ
(c)
F 1: Schematic representation of the parental lentiviral backbone (a), the subse�uent cloning intermediate (b), and the �nal dual-
promoter lentiviral vector used in the study (c). A detailed description of backbone components is available elsewhere [15].e intermediate
was derived from the parental clone by removing CMV and GPF; CMV was replaced with the cardiac-speci�c promoter (NCX1) and rtTA;
GFP was replaced by the Tet-responsive element cassette (TRE) and AIFsh. e resulting pTY2-NCX1-rtTA-TRE-AIFsh construct has been
named pNRTA for shortness. CMV: cytomegalovirus promoter; GFP, green �uorescent protein; MCS: multicloning site; fNCX1: feline Na+-
Ca2+ exchanger promoter; rtTA-reverse repressor of TRE; TRE, tet-responsive element; Tet: tetracycline; AIFsh: apoptosis-inducing factor-
short.
2.5. Apoptosis Induction and Cell Survival Measuring. Forty-
eight hours aer transduction, apoptosis was induced upon
incubating cells with 1𝜇𝜇g/mL Tet (Sigma Aldrich, St. Louis,
MA, USA). Cells were then washed and trypsinized, and live
cells were counted by trypan blue exclusion, at 4, 6, 8, and 24
hours of incubation with Tet.
e number of live cells was normalized by the number
of live, untransduced, untreated cells at each time point.
2.�. D�A �ragmentation Assay ����EL�� Immuno�uores-
cence. Apoptotic cell deathwasmeasured four hours aer the
addition of Tet by the deoxynucleotidyl transferase-mediated
dUTP nick end-labeling (TUNEL) method, using ApoAlert
DNA fragmentation assay kit (Clontech Europe, France),
and according to the manufacturer’s protocol. Images were
analyzed using a �eiss immuno�uorescence microscope.
2.�. Cell Lysis� Antibodies� and Immuno�uorescence. For im-
muno�uorescence analysis, HL-1 cells were grown on cover-
slips, �xed, and incubated twice for 10min with phosphate-
buﬀered saline (PBS) 0.1% Triton X-100 to permeabilize
plasma membranes; aer extensive washing with PBS+ (PBS,
0.1% glycine, and 0.5% BSA), cells were incubated with
primary antibody (anti-AIF antibody, 1 : 50) overnight at
4∘C. Cells were then washed again in PBS+ and incubated
with secondary antibody (donkey anti-goat, Fluorescein
isothiocyanate (FITC) conjugated, 1 : 500) for 1 hour at 37∘C.
Following extensive washing with PBS+, slides weremounted
with Vectashield and analyzed. All antibodies were diluted in
PBS+.
Goat anti-AIF antibody and donkey anti-goat FITC con-
jugated were obtained from Santa Cruz Biotechnologies.
2.8. Statistical Analysis. e statistical signi�cance was
assessed by calculating 𝑃𝑃 values from nonparametric two-
tailed Student’s 𝑡𝑡-test or ANOVAwhen 3 ormore groupswere
compared. e analyses were conducted using GRAPHPAD
Prism 5.00 soware.
3. Results and Discussion
3.1. Dual-Promoter Lentiviral Vectors for Inducible Expression
in Cardiomyocytes. Dual-promoter lentiviral vectors for tis-
sue speci�c expression of selected transgenes have already
been described for several highly specialized tissues [21, 22].
Here, we applied and further improved this system to obtain
the conditional expression of a transgene in cardiomyocytes.
is was achieved by placing AIFsh under control the of
the feline Na+-Ca2+ exchanger (NCX1) cardiac-speci�c pro-
moter [18] and Tet-inducible activator rtTA. To this purpose,
we engineered TY2-CMV-GFP, an HIV-1 vector expressing
the green �uorescent protein (GFP) under the control of cyto-
4 BioMed Research International
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F 2: Inducible AIFsh expression in cardiac cells. HL-1 cardiac cells were transduced with the pNRTA vector and assessed for transgene
expression 48 hours later. Transgene expression was evaluated before or aer induction by exposing cells to 1 𝜇𝜇g/mL Tet for 4 hours. (a)
Cells were then processed for immuno�uorescence with an anti-AIF antibody and an FITC-con�ugated secondary antibody.e panel shows
sample images of HL-1 cells treated as follows: untransduced (upper), transduced and uninduced (middle), and transduced and induced
(lower). �API staining, green �uorescence, and a merging of the two channels are shown. (b) �uantitation of immuno�uorescent slides of
transducedHL-1 cells either uninduced (−Tet) or induced (+Tet).e amount of �uorescent cells is expressed as a fraction of green �uorescent
cells over non�uorescent cells in the �eld counted.
megalovirus (CMV) promoter. rough the intermediates
described in Section 2, the CMV promoter and GFP were
replaced by two expression cassettes.eCMVpromoter was
replaced by the cardiac-speci�c promoter (NCX1) and rtTA�
GFP was replaced by the Tet-responsive element cassette
(TRE) and AIFsh. e resulting construct (pTY2-NCX1-
rtTA-TRE-AIFsh) has been named pNRTA for shortness
(Figure 1).
Cell-speci�c and Tet-dependent expression of AIFsh was
tested by transducing TY2-TRE-AIFsh in mouse cardiac
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F 3: Continued.
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F 3:Apoptosis induction and cell survival. 48 hours aer transductionwith pNRTAvector, apoptosiswas induced inHL-1 cells following
the exposure to Tet as indicated. Cells were then washed and trypsinized, and live cells were counted by trypan blue exclusion. (a) Number
of viable, NRTA-transduced, HL-1 cells aer exposure to the indicated amount of Tet for 24 hours. (b) Number of viable, untransduced,
HL-1 cells aer exposure to the indicated amount of Tet for 24 hours. (c) Number of viable HL-1 cells (transduced and untransduced) aer
exposition at the indicated amount of Tet for 24 hours. (d) HL-1 cells transduced with pNRTA vector. (e) HeLa cells transduced with pNRTA
vector. (f) HL-1 cells transduced with empty pTY2 vector. (g) HeLa cells, transduced with empty pTY2 vector. Cell survival in panels (d) to
(g) are expressed as a fraction of live cells over total cells. −Tet: cells unexposed with tetracycline; +Tet: cells exposed to 1 𝜇𝜇g/mL tetracycline.
HL-1 cells. e human cervix epithelial adenocarcinoma
(HeLa) cells were tested in parallel and used as a negative
control. Immuno�uorescence analysis with an anti-AIF anti-
body demonstrated an increase in Tet-dependent expression
of AIFsh transgene aer Tet induction (1𝜇𝜇g/mL). In contrast,
expression was consistently below 10% in nontransduced
cells and in transduced, Tet-untreated cells (Figures 2(a) and
2(b)). Similarly, the number of AIFsh-expressing cells in
induced versus noninduced cells increased and was a high
statistical signi�cance (𝑃𝑃 𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃; the number of AIFsh
expressing cells was calculated as the ratio between green
�uorescent versus non�uorescent cells in each �eld counted.
e eﬃciency of transduction was inferred with HL-1 cells
transduced with pTY2-CM�-�F� and examined for �uores-
cence by �ow cytometry; the percentage of transduced cells
was estimated to be between 60% and 70% in all transduction
experiments (data not shown). HeLa cells transduced in
parallel showed no transgene expression even aer induction
(data not shown), thus con�rming that the expression was, in
fact, cardiomyocyte speci�c.
3.2. Tetracycline-Regulated Transgene Expression. To deter-
mine the time-course kinetic of the transgene expression,
HL-1 cells were transduced with the inducible vector and
cell survival was evaluated aer the exposure to Tet. First,
the optimal, nontoxic concentration of Tet was estimated
by treating cells with the increasing concentrations of the
drug and evaluating cell survival aer 24 hours. e optimal
concentration, that is the best induction with minimal the
toxicity versus the similarly treated nontransduced cells was
1 𝜇𝜇g/mL (Figures 3(a), 3(b), and 3(c)). is concentration
was, therefore, used in the following time-course experiment
in which cell survival was measured aer 2, 4, 6, 8, and 24
hours of Tet addition and consequent AIFsh induction. Cell
counts showed a marked reduction (∼50%) in cell survival
over time in transducedHL-1 cells treatedwithTet, compared
to untreated cells (Figure 3(d)). ese results indicated that
the apoptotic process occurred predominantly between 4 and
24 hours aer AIFsh induction, while no further decrease
in cell survival was observed at later time points (data not
shown). A small percentage of cell death could still be
observed in untreated cells and can probably be ascribed to
TRE promoter leakage.
To con�rm the cell speci�city of the observed eﬀect, we
performed the same experiments in HeLa cells. Despite good
eﬃciency of transfection (65%), survival of this noncardiac
cell line was not aﬀected upon Tet stimulation of gene expres-
sion (Figure 3(f)), thus proving that the eﬀect on cell survival
is lineage speci�c and driven by the cardiomyocyte-speci�c
promoter.
To rule out the possibility that the observed reduction of
cell survivalwas either due toTet treatment or lentiviral trans-
duction, we assessed cell survival in nontransducedHL-1 and
HeLa cells, treated or untreated with Tet (Figure 3(e)), and in
HL-1 and HeLa cells transduced with the lentiviral backbone
lacking the inducible system and the pro-apoptotic transgene
(Figure 3(g)). e results clearly showed that the reduction
in cell survival was not due to Tet treatment or vector
transduction, thus con�rming the speci�city and inducibility
of the system.
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F 4: Measurement of apoptotic cell death.e amount of apoptotic cell death was determined aer 4 hours exposure to 1 𝜇𝜇g/mL Tet by
using the deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL), a standard method for evaluating DNA fragmentation.
Following �uorescent labeling, cells were �xed on slides and analy�ed by �uorescence microscopy. (a) �ells stained with DAPI (nuclear dye),
�uorescein-labeled dUTP, and merging of the two channels. (b) �uanti�cation of TUNEL-positive cells, expressed as the fraction of green
�uorescent cells over non�uorescent cells in each of the � �elds counted for each condition. Negative control: nontransduced cells; positive
control: cells treated with DNaseI; −Tet: HL-1 cells transduced with pNRTA vector and nontreated with Tet; +Tet: HL-1 cells transduced with
pNRTA vector and treated with Tet for 4 hours.
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3.3. Tet Treatment Triggers Apoptosis in Transduced HL-
1 Cells. To provide evidence that Tet induction of AIFsh
expression was eﬀectively leading to cell death by apoptosis,
we performed a TUNEL, an immuno�uorescence assays on
transduced HL-1 cells (Figure 4(a)).
is analysis showed a strong �uorescent signal, corre-
sponding to DNA fragmentation, 4 hours aer Tet addition
in approximately 50% cells (Figure 4(b)) (consistent with
the decrease in cell survival found in the cell counts). In
contrast, no signal was observed in either nontransduced or
transduced but Tet-untreated cells. Statistical analysis showed
that the diﬀerence in �uorescence was highly signi�cant (𝑃𝑃 𝑃
0.001) when induced cells were compared to noninduced
cells or the negative control, while no signi�cance was found
when comparing the �uorescence of the negative control with
that of uninduced cells.
ese results showed that pTY2-TRE-AIFsh is an eﬃ-
cient and reliable in vitro system for inducing apoptosis of
cardiomyocytes in a tightly regulated manner. e system
consists of a lentiviral vector carrying a dual-promoter system
that allows speci�c induction and restricted the expression of
genes in cardiomyocytes. Inductionwas achieved bymeans of
rtTA-regulated transcription of a cell type-speci�c promoter,
whereas the transgene expression was driven by the TRE.
In comparison to other gene delivery systems, in which the
transfected genome is delivered in two separate plasmids,
dual-promoter lentiviral vectors with modular design boast
several advantages as they allow easy replacement of the
transgenes and permit stable and regulatable expression of
both transcriptional units in the recipient cells.
e evidence that neither latent expression from TRE in
the absence of Tet (in HL-1 cells) nor the administration of
Tet in transduced HeLa cells signi�cantly altered the cells
viability strengthens the validity of our system as a potential
molecular tool for further in vivo studies.
Lentiviral vectors are well known as tools to deliver and
stably express transgenes in a variety of cell types, including
cells of cardiac lineage [14], and have been successfully used
in a number of gene therapy studies showing their ability
to sustain long-term transgene expression in vivo (reviewed
in [23]). Moreover, the type of vector developed here is
suitable for “lentivirus trangenesis,” an interesting strategy
recently proposed as an alternative to direct microinjec-
tion of DNA into pronuclei [8]. Lentiviruses can eﬃciently
transfer and integrate cDNAs into the host cell genome of
oocytes and early embryos, thus making possible the genetic
manipulation of animals other than mice, including large
mammals.e transgene can then be activated or deactivated
at any time of postnatal life simply by administering or
withdrawing Tet. In agreement with this idea, Tet-regulated
transgene activation has been successfully used in several
transgenesis approaches in vitro and in vivo. ese studies
also demonstrated long-term responsiveness of the inducible
system to Tet (reviewed in [24, 25]).
Wencker et al. have shown, in genetically modi�ed mice,
that very low levels of myocyte apoptosis are suﬃcient to
cause a lethal, dilated cardiomyopathy in otherwise normal
hearts [5], supporting the hypothesis that programmed cell
death plays a major role in clinical heart failure [2, 3]. ere-
fore, a potential application of our construct would be
the generation of clinically relevant, large animal models
of dilated cardiomyopathy, which are currently unavailable
and urgently required to study pathophysiological alterations
and test new therapeutic interventions [26]. Alternatively,
the dual-promoter system can be delivered to somatic cells
during the adult life. In such a case, it might be necessary
to produce an ad hoc vector to enhance the eﬃciency of
the transduction of adult cardiomyocytes, which have proven
almost completely refractory to conventional vector systems
[27].
4. Conclusions
Our results oﬀer a new and interesting tool that can be
exploited to study apoptosis-related pathological conditions.
Given the potential development of lentivirus transgenesis
to develop novel and engineer existing animal models in
the near future, the lentiviral construct described here may
pave the way to produce clinically relevant models for further
dilated cardiomyopathy research.
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